Apollo Hospitals Q2 revenue rises 23%, profit up 32% on broad-based growth

CHENNAI: Apollo Hospitals Enterprise Ltd on Wednesday reported a 32% year-on-year growth in consolidated net profit to ₹630 crore for the quarter ended September 2026 (Q2 FY27), on broad-based growth across hospitals, pharmacy and diagnostics.

Consolidated revenue rose 23% to ₹7,615 crore, from ₹6,189 crore in the same quarter last year. EBITDA rose 29% to ₹1,191 crore, with margin expanding to 15.64% from 14.95%.

For the first half of FY27, consolidated net profit grew 33% to ₹1,211 crore on revenue growth of 22% to ₹14,547 crore.

Growth was driven by volume increase, higher occupancy and complex clinical work. Hospital occupancy in Q2 stood at 73%, up from 69% a year ago. Inpatient volumes grew 14%, while average revenue per patient increased 8% to ₹1,86,880.

Healthcare Services revenue increased 23% to ₹3,900 crore. Growth was led by oncology (28%), gastroenterology (27%), urology (26%), and cardiac and orthopaedic (20% each).

International patient services revenue grew 37% year-on-year, aided by a rebound in inflow from Bangladesh and good traction in Africa.

Apollo HealthCo, which operates pharmacy distribution and digital health, recorded revenue growth of 23% to ₹3,286 crore, with EBITDA rising to ₹193 crore from ₹110 crore.

Apollo Health and Lifestyle, which includes primary care and diagnostics, saw gross revenue of ₹429 crore, up 20% year-on-year. Diagnostics revenue alone grew 24% to ₹227 crore.

Commenting on the results, Dr. Prathap C. Reddy, Founder and Chairman, Apollo Hospitals Group, said the performance was supported by robust volume increase in core specialties and high complexity clinical work.

The company said its expansion programme to add over 5,800 beds over five years remains on track.